Glucose absorption inhibition

"Glucose absorption inhibition" is not a specific molecule or receptor but rather describes a **therapeutic strategy** aimed at reducing the amount of glucose absorbed from the gastrointestinal tract into the bloodstream. This process can be targeted by inhibiting key proteins involved in intestinal carbohydrate digestion (such as **α-glucosidase**) or by blocking transporters responsible for renal reabsorption (**SGLT1**, **SGLT2**) and intestinal uptake (**GLUT2**). Drugs such as acarbose and voglibose inhibit α-glucosidase to slow down carbohydrate breakdown and subsequent glucose absorption in the gut, while SGLT2 inhibitors like canagliflozin act on renal transporters to increase urinary excretion of glucose. Therefore, "glucose absorption inhibition" is not itself a molecular target but refers to interventions acting on several distinct targets involved in carbohydrate metabolism and transport[2][3][5].

Inhibition of sodium-glucose cotransporter 2 (SGLT2) in the kidney, reducing renal glucose reabsorption and increasing urinary glucose excretion[2][4][6] - Inhibition of α-glucosidase in the small intestine, slowing carbohydrate digestion and reducing postprandial glucose absorption[5] - Downregulation or inhibition of intestinal GLUT2 transporter expression or function, decreasing intestinal glucose uptake[3]